AlphAIalphai — Financial news for AI agents
finanznachrichten.deJUL 296 min read$IART

Integra LifeSciences Holdings Corporation: Integra LifeSciences Reports Second Quarter 2026 Financial Results

Integra LifeSciences Holdings (Nasdaq: IART) reported Q2 2026 results for the quarter ended June 30. Revenues were $418.8M, up 0.8% reported. GAAP diluted EPS was $0.06 versus $(6.31) a year earlier; adjusted EPS was $0.56 versus $0.45. The company updated 2026 reported revenue guidance to $1.654B-$1.695B and reaffirmed organic growth of 0.8%-3.3% and adjusted EPS of $2.40-$2.50.

Original reporting
finanznachrichten.de
Published Jul 29, 2026, 10:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$IART
Bullish
medium confidence
Mentioned
$IART
Relevance
8/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$IARTBullishMed
01

Why it matters

The release combines a Q2 earnings/margin update with a guidance adjustment for FY reported revenue (FX impact) while reaffirming organic growth and adjusted EPS. It also adds operational milestones (Braintree production started, SurgiMend relaunch on track), which can influence expectations for future revenue and gross margin.

02

Market read

Traders can reassess near-term expectations for earnings quality (margin/EBITDA), the credibility of the SurgiMend relaunch timeline, and how much of the guidance change is non-operational FX noise.

03

What to watch

Net debt of $1.6B and leverage at 4.1x could constrain upside if refinancing conditions worsen, despite reaffirmed adjusted EPS guidance.

Relevance 8/10Novelty 7/10Timing: today’s Q2 print and updated FY reported revenue guidance, ahead of the scheduled 8:30 a.m. ET conference call

Background

Integra is a medical technology company focused on neurosurgery and tissue reconstruction, with SurgiMend relaunch planned for Q4 2026 and a Braintree manufacturing facility ramp underway.

Company-level read

Ticker impact

$IARTBullishMedium confidence
Context

Integra reported Q2 2026 results and updated full-year reported revenue guidance to $1.654B-$1.695B due to a stronger U.S. dollar.

Expected impact

Moderate positive bias for the stock as adjusted EPS beat the prior year and gross margin improved, with FX headwind framed as non-core.

Evidence & confidence

The release provides multiple fresh datapoints: Q2 revenue, GAAP/adjusted EPS, margin expansion, and a specific guidance range change tied to FX. It also reiterates organic growth and adjusted EPS, reducing uncertainty versus a full guidance reset.

Market effects

Sector

Medical device and surgical supply names may see read-across from margin and execution commentary, especially around tissue reconstruction and specialty surgery demand.

Regional

FX sensitivity highlighted via stronger U.S. dollar may affect reported results for other multinationals with similar revenue mix.

Global

Limited broader macro spillover; the main global signal is company-specific manufacturing progress and product relaunch timing.

Counterpoint

What could challenge this read

Because the FY reported revenue guidance change is explicitly FX-driven, the market may discount it and instead scrutinize whether organic growth and SurgiMend ramp can sustain earnings power.

Key entities

  • company
    Integra LifeSciences Holdings Corporation

    Reported Q2 2026 financial results, updated FY reported revenue guidance for FX, reaffirmed organic growth and adjusted EPS, and stated Braintree production has started for a Q4 SurgiMend relaunch.

Read at source← All news

Related articles

AUG 5
$IARTMed

Read Analyst Questions From Integra LifeSciences’s Q2 Earnings Call

Integra LifeSciences (IART) reported Q2 revenue of $418.8M, roughly flat year over year and slightly above estimates, with adjusted EPS of $0.56 vs $0.48 expected. Management cited reimbursement pressures and product mix for margin compression, while adjusted EPS outperformance reflected execution and tariff dynamics. Full-year revenue guidance was reconfirmed at $1.67B midpoint and adjusted EPS at $2.45.

financialcontent.com4 min
AUG 1
$IARTMed

IART Q2 Deep Dive: Flat Revenue, Margin Pressure, and Operational Realignment Shape Outlook

Integra LifeSciences (IART) reported Q2 revenue of $418.8M, flat YoY and slightly above estimates, with adjusted EPS of $0.56 (vs $0.48) and adjusted EBITDA of $78.41M. Operating margin fell to 4.6%. The company reconfirmed FY revenue guidance of $1.67B and adjusted EPS of $2.45, citing cost savings and operational realignment amid reimbursement and competitive pressures.

finance.yahoo.com6 min
JUL 30
$IARTMedAI 8/10

Integra LifeSciences Q2 Earnings Call Highlights

Knight said Integra retained its full-year EPS outlook because it has adjusted its tariff assumptions and expects higher interest expense in the second half tied to a potential refinancing of bank debt. The company still estimates its total tariff exposure for the year at about $0.10 per share. "We do not expect any operational headwinds to offset some of the upside that we saw, but we do expect to see interest expense headwinds," Knight said.

yahoo.com6 min
JUL 29
$IARTMedAI 8/10

Why Integra LifeSciences (IART) Shares Are Sliding Today

Integra LifeSciences (IART) shares fell 10.1% after Q2 results. The company reported adjusted EPS of $0.56 above estimates, but revenue was flat at $418.8 million and operating margin fell to 4.6% from 7.9%. Q3 revenue guidance was about $417.5 million, and full-year revenue guidance was reconfirmed.

financialcontent.com6 min
JUL 29
$IARTMed

Integra LifeSciences Swings To Profit In Q2; Trims FY26 Revenue Outlook

Integra LifeSciences (IART) reported Q2 net earnings of $4.48 million, or $0.06 per share, versus a year-ago net loss. Adjusted EPS was $0.56. Revenue rose 0.8% to $418.76 million. For Q3, it expects adjusted EPS of $0.53-$0.61 on $410-$425 million revenue. For FY26, it trimmed revenue guidance to $1.654-$1.695 billion and reiterated adjusted EPS of $2.40-$2.50.

rttnews.com3 min